Kiniksa Pharmaceuticals International, plc

Thank you for standing by and welcome to the Conexa Pharmaceuticals fourth quarter and full year 2021 earnings conference call and corporate update. At this time, all participants are in listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during the session, you'll need to press star 1 on your telephone. As a reminder, today's program may be recorded. I would now like to introduce your host for today's program, Rachel Frank, Investor Relations.

Please go ahead. Thank you, Operator. Good morning, everyone, and thank you for joining Connex's call to discuss our fourth quarter in full year 2021 financial results and corporate update. A press release highlighting these results can be found on our website under the Investors and Media section. As for the agenda, our Chief Executive Officer, Sanj K. Patel, will start with an introduction. Ross Mote, our Chief Commercial Officer, will provide an update on our ARCLOS commercial execution. Eben Cesari, Connex's Chief Operating Officer, will follow with a brief review of a recently announced strategic collaboration as well as our portfolio. Then Mark Ragosa, our Chief Financial Officer, will review our fourth quarter and full year 2021 financial results. And finally, Sanz will return for closing remarks and to kick off the Q&A session for which John Paolini, our Chief Medical Officer, will also be on the line. Before getting started, Please note that we will be making forward-looking statements today that are subject to risks and uncertainties that may cause actual results to differ materially from these statements. A review of such statements and risk factors can be found on this slide, as well as under the caption, Risk Factors, contained in our SEC filings. These statements speak only as of the date of this presentation, and we undertake no obligation to update such statements except as required by law. With that, I will turn it over to Sanj.

Thanks, Rachel, and good morning, everyone. I'm really happy to review our fourth quarter and full year 2021 results today. We continue to make a lot of progress in bringing Arclist to patients in need and executing across our portfolio of clinical stage product candidates. I'm delighted to report that the net revenue for Arclist for the fourth quarter of 2021 was $18.7 million. And the total ARCALIS net revenue since our launch in April 2021 was $38.5 million. As Rachel said, Ross will cover our commercial performance in more detail. And as you'll hear, we are very pleased with the success of Connexus' first commercial launch. This has been marked by continuous growth in prescriber adoption, expansion in payer coverage, and strong patient adherence. And moving forward, we plan to continue this robust commercial execution. In addition to the launch, we remain focused on building the maximum value across our portfolio of clinical stage product candidates. And these are Vicksirilumab, KPL404, which is our CD40 program, and Mabrilimumab. Evan will provide an overview of each of these programs. and we continue to be energized by our progress across the entire portfolio, and we believe that we're well-positioned for longer-term growth. So with that, I'll turn it over to Ross to discuss our commercial performance in more detail. Ross?